01—Abstract
Summary
Summary of the 8-K filed July 16, 2026. Cited figures are marked; the original filing is the authoritative source.
Abbott reported second-quarter 2026 net sales of $12.593 billiona, up 13.0% on a reported basis and 4.8% on a comparable basis.
The reported growth was driven mainly by the March 23, 2026 acquisition of Exact Sciences, which added $811 millionb to Q2 sales and is consolidated as Abbott's Cancer Diagnostics business. Comparable growth was led by Medical Devices (+8.4%, with Electrophysiology and Diabetes Care strong) and Established Pharmaceuticals (+8.7%), while Nutrition declined 3.6% and Rapid/Molecular Diagnostics fell 8.0% on lower respiratory virus testing. GAAP results were weaker.
GAAP diluted EPS was $0.53c versus $1.01 a year earlier, and GAAP net earnings fell 47.8% to $928 million. The decline reflects $1.362 billion of after-tax specified items ($0.78 per share), including $385 million of legal reserves tied to an agreed-in-principle settlement, intangible amortization of $658 million (up from $420 million), and acquisition-related costs. Interest expense rose to $299 million from $50 million, and the effective GAAP tax rate was 39.1%, inflated by roughly $240 million of adjustments related to a previously recognized non-cash deferred tax benefit and about $110 million of net tax expense on prior-year tax positions.
Adjusted diluted EPS rose 4.0% to $1.31d from $1.26. Management reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5% and raised the adjusted diluted EPS range to $5.45 to $5.60 from $5.38 to $5.58, implying a modest midpoint increase. Third-quarter adjusted EPS is guided to $1.38 to $1.46.
Management expects sales and earnings growth to accelerate in the second half. Abbott also returned $2.1 billion to shareholders in the quarter and declared its 410th consecutive quarterly dividend of $0.63 per share.
02—Key points
Key Highlights
- Reported Q2 sales rose 13.0% to $12.593 billion; comparable sales grew 4.8%, with Exact Sciences contributing $811 million of reported growth.
- GAAP diluted EPS fell to $0.53 from $1.01 and GAAP net earnings declined 47.8% to $928 million, driven by $1.362 billion of after-tax specified items, including $385 million of legal reserves.
- Adjusted diluted EPS grew 4.0% to $1.31 from $1.26, excluding intangible amortization ($658 million), acquisition costs, legal reserves, and other specified items.
- Full-year 2026 adjusted EPS guidance was raised to $5.45 to $5.60 from $5.38 to $5.58, while comparable sales growth guidance of 6.5% to 7.5% was reaffirmed.
- Medical Devices comparable sales grew 8.4%, led by Electrophysiology (+13.4%), Rhythm Management (+9.5%), and Diabetes Care (+9.0%); continuous glucose monitor sales rose 9.5% on a comparable basis.
- Cancer Diagnostics generated $919 million in sales with 13.3% comparable growth, driven by mid-teens growth in Cologuard, while Nutrition declined 3.6% comparably on lower volumes.
- Interest expense increased to $299 million from $50 million, reflecting acquisition financing, and amortization rose 56.8%, which will continue to weigh on GAAP earnings.
03—Questions
Frequently Asked Questions
Why did GAAP earnings fall sharply even though adjusted EPS grew?
GAAP net earnings were reduced by $1.362 billion of after-tax specified items in Q2 2026, or $0.78 per share. These include $658 million of intangible amortization, mostly from the Exact Sciences acquisition, $385 million of legal reserves for an agreed-in-principle settlement, acquisition-related costs, and investment impairments. Higher GAAP tax expense of about $240 million related to a previously recognized non-cash deferred tax benefit and about $110 million on prior-year tax positions also contributed.
How much of the reported sales growth came from the Exact Sciences acquisition?
Exact Sciences, acquired March 23, 2026, contributed $811 million of Q2 sales. Total reported growth was 13.0%, but comparable growth, which excludes acquired sales in both periods along with FX and a prior multi-year Structural Heart compensation agreement, was 4.8%. Underlying growth therefore came mostly from Medical Devices and Established Pharmaceuticals, with Nutrition and Rapid/Molecular Diagnostics still declining.
Did Abbott change its 2026 outlook?
Yes, partially. Full-year comparable sales growth guidance was reaffirmed at 6.5% to 7.5%. Adjusted diluted EPS guidance was raised to $5.45 to $5.60 from $5.38 to $5.58, a modest increase at the midpoint. Q3 2026 adjusted EPS is projected at $1.38 to $1.46. Abbott did not provide GAAP guidance because it cannot reliably forecast items such as restructuring, impairments, acquisition costs, and FX.
What is the outlook for the Nutrition and Rapid/Molecular Diagnostics segments?
Nutrition sales fell 3.1% reported and 3.6% comparable, mainly due to lower volumes and strategic pricing actions taken in Q4 2025. Management says these actions and new product launches are improving performance, with sequential sales up $127 million from Q1. Rapid and Molecular Diagnostics fell 7.3% reported and 8.0% comparably due to lower respiratory virus testing versus the prior year. The filing does not quantify expectations for these segments.
Is the dividend safe, and how much was returned to shareholders?
Abbott declared its 410th consecutive quarterly dividend of $0.63 per share, payable August 17, 2026, to holders of record on July 15, 2026. The company has increased its dividend for 54 consecutive years and is an S&P 500 Dividend Aristocrat. In Q2 it returned $2.1 billion to shareholders through dividends and share repurchases. Dividend coverage is strong on an adjusted basis, though GAAP earnings were much lower this quarter.
04—Continue